Vice President and Equity Research Analyst at Jefferies
Fiona Gia is a Vice President and Equity Research Analyst at Jefferies, specializing in coverage of the biotechnology and pharmaceutical sectors with a primary focus on companies such as Gilead Sciences, Amgen, and Vertex Pharmaceuticals. She is recognized for her comprehensive analysis and has been noted in sector-specific rankings for her thorough due diligence and accuracy in stock recommendations, achieving a success rate above 65% with significant average returns benchmarked on industry platforms. Fiona began her research career in the early 2010s, holding previous positions at UBS and Leerink Partners before joining Jefferies in 2019, where she has expanded her sector influence and mentorship roles. She holds FINRA Series 7, 63, and 86/87 registrations and is known for her presentations at major healthcare investment conferences as well as contributions to industry panels.
Fiona Gia asked for more characterization of the amylin agonist candidate that Viking has selected to move forward, specifically regarding its activity profile.
CEO Brian Lian responded that the compounds of greatest interest have a more balanced profile, with activity close to a 1:1 ratio when comparing calcitonin to amylin 3 receptor activity.